APPEN
7.3.2019 17:02:08 CET | Business Wire | Press release
Appen Limited today announced the achievement of ISO/IEC 27001:2013 accreditation for its facility in Cavite, Philippines to meet the rapidly growing demand for human-annotated datasets used by companies worldwide to train machine learning and artificial intelligence (AI) applications.
The facility was established to ensure commercial confidentiality and better support privacy management. Globally recognized, the ISO/IEC 27001:2013 standard defines the requirements for an Information Security Management System (ISMS), and a process-based approach for establishing, implementing, operating, monitoring, maintaining and improving the ISMS.
ISO/IEC 27001:2013 accreditation underpins Appen’s ability to work on datasets for clients that contain personally identifiable information – data that could potentially identify a specific individual – as well as other sensitive material, such as data related to new product development.
“Appen’s facility in the Philippines gives clients enhanced options to scale their AI programs with the assurance that their sensitive data and projects will remain secure,” said Mark Brayan, Appen’s chief executive officer. “It’s the perfect complement to our high-security facility in the U.K., and is an important part of our suite of secure at-home and in-facility solutions.”
Appen works with the world’s leading technology companies, as well as firms across all industries to provide high-quality data for their machine learning programs. Appen’s suite of secure solutions includes secure facilities as well as secure remote worker options designed to scale customers’ machine learning programs while maintaining data privacy. Use case examples range from voice recognition in smart speakers to geospatial analysis in self-driving cars, to intelligent search and online advertising results.
Industry analysts estimate the data collection and annotation market will be worth up to $19 billion – approximately 10% of the overall AI market – by 2025. The explosive growth is attributed to the need for high volumes of annotated data that are required to improve AI algorithm accuracy. Today, approximately one-third of AI applications require frequent or monthly data updates, and one-quarter of those need weekly updates, according to McKinsey Global Institute.
Datasets created by Appen include image, text, audio, video and relevance data, as well as speech and natural language data from over 130 countries and more than 180 languages and dialects.
The announcement today follows Appen’s recent reporting of record results of AU$364.3 million in 2018, representing 119% growth year-over-year.
During the company shareholder call last week, Brayan outlined Appen’s 2019 growth initiatives that include increasing technology development to improve the productivity of its global crowd of over 1 million skilled contractors who develop the AI training datasets in conjunction with Appen’s Client Services team. In addition to expanding Appen’s secure solutions, the company also plans to increase its full-time staff and investments in China, the largest AI market outside of the U.S.
Founded in 1996, Appen has office locations worldwide including Seattle, San Francisco, Detroit, and Beijing in addition to the Philippines, U.K. and its headquarters in Sydney.
About Appen
Appen is a global leader in the development of high-quality, human-annotated datasets for machine learning and artificial intelligence. Appen brings over 20 years of experience capturing and enriching a wide variety of data types including speech, text, image, and video. With deep expertise in more than 180 languages and access to a global crowd of over 1 million skilled contractors, Appen partners with technology, automotive and e-commerce companies — as well as governments worldwide — to help them develop, enhance and use products that rely on natural languages and machine learning.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005137/en/
Contact:
Jodie Ruby VP of Marketing jruby@appen.com 425-442-8014
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
